Case Reports| August 14 2000 Cerebrocutaneous Xanthoma disseminatum and Disseminated Demyelinating Encephalomyelitis Subject Area: Neurology and Neuroscience G. Pfeiffer; G. Pfeiffer aDepartments of Neurology, Search for other works by this author on: This Site PubMed Google Scholar C. Hagel; C. Hagel bNeuropathology, Search for other works by this author on: This Site PubMed Google Scholar B. Eckert; B. Eckert cNeuroradiology, Search for other works by this author on: This Site PubMed Google Scholar R. Zschaber; R. Zschaber dHematology and Oncology and Search for other works by this author on: This Site PubMed Google Scholar G. Gross; G. Gross fDepartment of Dermatology, University Hospital Rostock, Germany Search for other works by this author on: This Site PubMed Google Scholar C.M. Bamberger C.M. Bamberger eMedicine, University Hospital Hamburg-Eppendorf, Hamburg, and Search for other works by this author on: This Site PubMed Google Scholar Eur Neurol (2000) 44 (2): 123–124. https://doi.org/10.1159/000008211 Article history Published Online: August 14 2000 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation G. Pfeiffer, C. Hagel, B. Eckert, R. Zschaber, G. Gross, C.M. Bamberger; Cerebrocutaneous Xanthoma disseminatum and Disseminated Demyelinating Encephalomyelitis. Eur Neurol 1 August 2000; 44 (2): 123–124. https://doi.org/10.1159/000008211 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsEuropean Neurology Search Advanced Search Article PDF first page preview Close Modal This content is only available via PDF. 2000Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.
Various cutaneous manifestations of COVID-19 have been described and awareness of these findings is beneficial for clinicians for an accurate diagnosis.We present a case of skin findings consistent with acral microthrombi induced changes in an elderly gentleman who was positive for COVID-19.The patient had a mild course of COVID-19. Cutaneous findings resolved after one week from presentation with supportive care.This case highlights the importance of awareness of manifestations of COVID-19, which may assist in timely diagnosis and prevention of transmission.
Intranasal steroids (INSs) are recommended as first-line treatment for allergic rhinitis (AR) and a wealth of data exist supporting them as safe and effective. Our goal was to develop a consensus to help physicians choose between INSs by focusing on clinical profiles and patient preferences and providing expert advice on choosing the appropriate INS for each patient. Experts from specialties that manage patients with AR attended a roundtable meeting to discuss INS therapy. Besides comparisons with other pharmacologic agents, they examined the effects of INS on nasal anatomy, patient preferences for INS, and benefits of product selection based on patient profile. The literature on INSs in AR was reviewed, examining properties of the various drugs, delivery devices, formulations, and patient preference data. Nasal anatomy and physiology must be considered to optimize INS deposition in the nose. Teaching patients proper technique for using INS devices is important to prevent nasal injury and may help concentrate drug effect on affected tissues. INS therapies differ somewhat in biological properties and specific formulation; however, all are considered safe and effective treatment for AR. Patients exhibit different clinical profiles, which play a role in INS selection. Patients can clearly identify sensory characteristics of INS and therefore establish product preference. Patient preference also can guide physicians in choosing the appropriate agent for each patient. Control of AR requires a systematic approach to treatment selection and follow-up. Treatment selection should be matched with clinical profile and patient preferences.
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
